Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 7/20 | 0.37 |
| ▸ | THRB | P10828 | 7/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2928500 | 0.81 | THRA (0.58) | THRATHRB | |
| SCHEMBL30820666 | 0.81 | THRA (0.58) | THRATHRB | |
| SCHEMBL21940317 | 0.80 | THRA (0.48) | THRATHRBKMT2AMEN1 | |
| SCHEMBL21940320 | 0.80 | THRA (0.42) | THRATHRB | |
| SCHEMBL21749413 | 0.79 | THRA (0.50) | THRATHRBKMT2AMEN1TSHR | |
| SCHEMBL21749526 | 0.79 | THRB (0.51) | THRATHRBKMT2AMEN1GRM5 | |
| SCHEMBL23092352 | 0.75 | KAT2B (0.42) | KMT2AMEN1GRM5 | |
| SCHEMBL29577797 | 0.75 | KAT2B (0.42) | KMT2AMEN1GRM5 | |
| SCHEMBL21749433 | 0.73 | THRA (0.49) | THRATHRB | |
| SCHEMBL28555141 | 0.73 | THRA (0.41) | THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11203587-B2 | Thyroid hormone receptor beta agonist compounds | Terns, Inc. (US) | 2021-12-21 | — | — | US | disclosed |
| US-20200115362-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | TERNS PHARMACEUTICALS, INC. (KY) | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115362-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | THRB, THRA, TSHR | THRA 2/4885THRB 1/4885KMT2A 3633/4885 |
| US-11203587-B2 | Thyroid hormone receptor beta agonist compounds | THRB, THRA, TSHR | THRA 2/4885THRB 1/4885KMT2A 3633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.